Matthew Hersch & Stephen Crow
Founders, BlueGreen Clinical
Key Points
- Governance in clinical trials involves multiple layers of oversight
- Building trust with CROs is essential for successful partnerships
- Vendor management requires a structured lifecycle approach
- Effective communication can prevent misunderstandings and issues
- A risk-based approach is crucial for vendor qualification
- Future trends include increased technology integration in vendor management
Tom, Matthew, and Stephen discuss the complexities of governance and oversight in clinical trials, focusing on the vendor management lifecycle. They explore the importance of building strong relationships with CROs, the common mistakes made during vendor selection, and the significance of communication and transparency. The discussion also touches on contract negotiation, budgeting, and future trends in vendor management, emphasising the need for a win-win approach in these partnerships.
Chapters
About the Guest
Matthew Hersch & Stephen Crow
Founders, BlueGreen Clinical
With 20 years in Clinical Operations at a pioneering cannabinoid biotech, Matthew Hersch and Stephen Crow guided its growth from startup to mid-sized pharma. Their hands-on experience spans trial management, CRO oversight, team building, and GCP inspections.
In 2023, they founded BlueGreen Clinical to help biotechs build strong Clinical Operations foundations, sharing hard-won insights from their journey.
Want to discuss vendor oversight?
Book a consultation with Tom Lazenby to explore how Mayet can support your clinical QA needs.